Wetherby Asset Management Inc Nuvation Bio Inc. Transaction History

Wetherby Asset Management Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.24 - $5.85 $244,402 - $441,283	-75,433 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.6 - $8.83 $346,991 - $666,073	75,433 New	75,433 $397,000
Q3 2021 Nov 15, 2021	SELL	$7.78 - $10.0 $96,355 - $123,850	-12,385 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$9.22 - $14.48 $114,189 - $179,334	12,385 New	12,385 $115,000

158

157M

3.2K

98.7K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $584M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Wetherby Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Wetherby Asset Management Inc with notifications on news.